Clinical Trial: A Study to Evaluate Opevesostat (MK-5684) in Male Participants With Moderate Hepatic Impairment (MK-5684-009)

U.S., March 6 -- ClinicalTrials.gov registry received information related to the study (NCT06860243) titled 'A Study to Evaluate Opevesostat (MK-5684) in Male Participants With Moderate Hepatic Impairment (MK-5684-009)' on Feb. 28.

Brief Summary: Researchers have designed a study medicine called opevesostat as a new way to treat prostate cancer.

The purpose of this study is to learn what happens to opevesostat in a person's body over time (a pharmacokinetic [PK] study). Researchers will compare what happens to opevesostat in the body when it is given to healthy participants and participants with moderate hepatic (liver) impairment.

Study Start Date: April 11

Study Type: INTERVENTIONAL

Condition: Hepatic Impairment Healthy Participants...